Skip to main content

Table 4 Comparison of clinical outcomes during hospitalization between study groups

From: Real-world use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/β-blocks in Chinese patients before acute myocardial infarction occurs: patient characteristics and hospital follow-up

  AAβ (n, %) NO-AAβ (n, %) p value
Overall population
 Number 872 1833  
 MACE 69 (7.92) 108 (5.92) 0.049
 Cardiac-death 28 (3.21) 54 (2.96) 0.720
 All-cause death 29 (3.3) 62 (3.4) 0.939
 Target vascular reconstruction 1 (0.11) 0 (0) 0.148
 Recurrent myocardial infarction 39 (4.48) 45 (2.47) 0.005
 Malignant arrhythmia 2 (0.23) 2 (0.11) 0.451
 Cerebral infarction 3 (0.35) 7 (0.39) 0.874
 Cerebral hemorrhage 3 (0.35) 8 (0.44) 0.718
Matched population
 Number 226 452  
 MACE 13 (5.75) 21 (4.65) 0.53
 Cardiac-death 8 (3.54) 12 (2.65) 0.631
 All-cause death 8 (3.54) 13 (2.88) 0.638
 Target vascular reconstruction 0 (0) 0 (0)  
 Recurrent myocardial infarction 6 (2.65) 7 (1.55) 0.322
 Malignant arrhythmia 1 (0.44) 2 (0.44) 0.999
 Cerebral infarction 0 (0) 3 (0.67) 0.220
 Cerebral hemorrhage 0 (0) 4 (0.89) 0.157
  1. MACE = cardiac-death or target vascular reconstruction or recurrent myocardial infarction or malignant arrhythmia or cerebral infarction or cerebral hemorrhage
  2. MACE major adverse cardiovascular events